The primary endpoints of this study were the SD and CV of FPG during treatment with IDeg and IGlar in a randomised crossover trial in individuals with type 1 diabetes who underwent basal-bolus insulin therapy. This evidence concerns the gene INS and type 1 diabetes mellitus.